Medicine and Health
Posttraumatic Stress Disorder Psychopharmacology Algorithm Update—2024-2025
L. A. Bajor, C. Balsara, et al.
An evidence-informed update from Laura A. Bajor, Charmi Balsara, and David N. Osser refines pharmacological PTSD care: prazosin remains first-line for nightmares and disturbed sleep, SSRIs (sertraline or paroxetine) are recommended for residual daytime symptoms with aripiprazole as the first antipsychotic to consider for augmentation, while emerging options like TMS, stellate ganglion block, and pimavanserin are evaluated but not yet core treatments.
Related Publications
Explore these studies to deepen your understanding of the subject.

